LOR-253 had a reported 24-hour cell-viability IC50 of 73 µM in cadmium-transformed BPH1 prostate cells. This cellular endpoint should not be interpreted as a biochemical MTF1 inhibition constant. [2]
In a 5-day viability assay, BRCA2-deficient HCT116 B18 and B46 clones were more sensitive to APTO-253 than BRCA2-proficient HCT116 cells. The result supports genotype-dependent sensitivity in this paired-cell system. [3]
APTO-253 pretreatment reduced TGF-β-induced α-SMA mRNA in control MRC5 lung fibroblasts, with a smaller suppressive effect in KLF4-knockdown cells. The experiment used 250 nM APTO-253 for 36 hours before a 48-hour TGF-β challenge. [1]
LOR-253 concentration response in CTBPH1 cells
Cell-based study · Cadmium-transformed human BPH1 prostate cells (CTBPH1) [2]
The authors report a 24-hour cellular viability IC50 of 73 µM. This is a model-specific cellular endpoint, not a biochemical MTF1 inhibitory potency.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration series shown from 0 to 100 µM
- Exposure duration
- 24 h
- Method
- Cell treatment with LOR-253
- Reported limits
- Drug-series assay chemistry, vehicle and IC50 fitting method are not explicit. Shared statistics states triplicates and mean ± SD, without identifying independent biological repeats for this panel.
Methods and source locations
Compound reported in the paper: LOR-253; Compound label in the paper: LOR-253
Applicable to the named SKU at compound level; no claim that the current AdooQ lot was tested.
Results: Cadmium fails to restore ZIC2 function in MTF1 knockdown CTBPH1 cells; Figure 3B; Materials and Methods: Cell lines and reagents, Viability assay
CTBPH1 cell viability after 24 hours: Cell viability concentration response in Figure 3B, normalized to the zero-concentration condition. The Viability assay methods describe trypan blue for shRNA experiments but do not explicitly establish the assay used for the LOR-253 series. Shared Statistical analysis states cell-culture experiments were performed in triplicates and data are mean ± SD; the drug panel does not identify independent biological repeats. — Results: Cadmium fails to restore ZIC2 function in MTF1 knockdown CTBPH1 cells; Figure 3B; Materials and Methods: Cell lines and reagents, Viability assay
BRCA2-deficient HCT116 clones show greater APTO-253 sensitivity
Cell-based study · Human HCT116 BRCA2-proficient cells and BRCA2-deficient B18 and B46 clones [3]
After 5-day treatment, both BRCA2-deficient clones showed lower viable-cell fractions across the APTO-253 response series than the BRCA2-proficient cells. Olaparib was tested separately as a comparator.
Literature-Reported Treatment Conditions
- Treatment concentration
- APTO-253 series plotted over 0–0.4 µmol/L
- Exposure duration
- 5 days
- Method
- Separate concentration-response viability assays
- Co-treatment
- None; olaparib was a separate comparator, not a combination.
- Reported limits
- Exact IC50 values, replicate count for panel E and vehicle identity for this response series are not specified in the acquired main-text assay description/caption.
Methods and source locations
Compound reported in the paper: APTO-253; Compound label in the paper: APTO-253
Parent-compound cellular result; no iron-complex-to-parent dose conversion or current AdooQ lot validation.
Figure 3E and caption; Results: BRCA1/2-deficient cells are hypersensitive to APTO-253; Materials and Methods: Drugs and reagents, Cell types and culture, Cytotoxicity study
Genotype-associated difference in viable-cell fraction: 5-day CellTiter 96 AQueous one solution MTS assay; Figure 3E. The curves report percent of vehicle control and vertical bars indicate ±SEM. No exact IC50 is extracted. — Figure 3E and caption; Results: BRCA1/2-deficient cells are hypersensitive to APTO-253; Materials and Methods: Drugs and reagents, Cell types and culture, Cytotoxicity study
KLF4 knockdown attenuates the fibroblast response to APTO-253
Cell-based study · Control and CRISPR-mediated KLF4-knockdown MRC5 human lung fibroblasts stimulated with TGF-β [1]
APTO-253 pretreatment reduced TGF-β-induced α-SMA mRNA in control fibroblasts. This suppression was substantially attenuated, rather than abolished, in KLF4-knockdown cells, supporting a contribution from KLF4 inducibility.
Literature-Reported Treatment Conditions
- Treatment concentration
- APTO-253 250 nM; subsequent TGF-β 2 ng/mL (Methods default concentrations)
- Exposure duration
- APTO-253 for 36 h, followed by TGF-β stimulation for 48 h
- Method
- Pretreatment and subsequent differentiation challenge
- Co-treatment
- TGF-β is the experimental differentiation stimulus.
- Reported limits
- The supplemental panel does not specify vehicle identity or whether APTO-253 was removed when TGF-β was added.
Methods and source locations
Compound reported in the paper: APTO-253; Compound label in the paper: APTO-253
Nominal APTO-253 research effects in this cell model; no current AdooQ lot or exact salt-state equivalence validation.
Supplemental Figure 8 (official supplemental PDF p. 9); Results: APTO-253–mediated suppression of fibroblast activation depends on KLF4 inducibility; Methods: Reagents, fibroblast differentiation, qPCR, Statistics
TGF-β-induced α-SMA mRNA in control versus KLF4-knockdown fibroblasts: qPCR with human GAPDH reference; Supplemental Figure 8: mean ± SEM of 3 independent experiments; *P < 0.05, 2-way ANOVA. No fold values estimated from bars. — Supplemental Figure 8 (official supplemental PDF p. 9); Results: APTO-253–mediated suppression of fibroblast activation depends on KLF4 inducibility; Methods: Reagents, fibroblast differentiation, qPCR, Statistics